DRUGS
47 articole · RSS
Antibiotice Iasi Posts Higher Profit, Of RON19.19M, In 1H/2017
Romanian state-run drugmaker Antibiotice Iasi (ATB.RO) on Thursday reported a profit of RON19.19 million in January-June 2017, higher than RON16.4 million in the year-earlier period, according to data sent to the Bucharest Stock Exchange.
Mylan Romania Sold RON160M Worth Of Drugs In 2016
Mylan Romania, the local division of U.S. pharmaceutical company Mylan, one of the world’s largest drugmakers, posted sales of RON160 million in 2016, reaching a market share of 1.6% two yea...
Romania And Bulgaria To Jointly Negotiate With Drug Makers
The Romanian Government approved on Wednesday, through Memorandum, the negotiation of a cooperation agreement with Bulgaria, which stipulates, among others, that the two countries can conclu...
Romania, Among Top 5 Emerging Markets For New Terapia Owner Sun Pharma
Sun Pharma group, founded by Dilip Shanghvi, one of India’s wealthiest businessmen, generates sales of over $100 million in Romania, the second largest market in Europe after Russia. Romania...
Polisano Takes New Loans, Hires New Managers
Polisano drug wholesaler, part of the Sibiu group of the same name, in the last week of 2014 signed an agreement for a EUR10 million (RON44 million) loan with Eximbank, for working capital....
Roche Romania’s Expectations For 2015
Roche Romania, the largest player on the local pharmaceutical market, estimates the industry will register tepid growth, of 2-3%, in 2015.
Antibiotice Feels The Pinch Of Falling Prices And Russian Crisis
Romanian state-run drug maker Antibiotice Iasi says its exports, weighing 30% in revenue, felt the fallout of declining prices internationally, as well as of the crisis in Russia and Ukraine...
Romania, Almost Inexistent In Terms Of European Drug Exports
Romania’s drug and pharmaceutical product exports rose by 40% in 2011-2013, going beyond EUR1 billion last year, according to Euromonitor data.
How Much Did Europharm Bring GSK In More Than A Decade?
Romanian medicine plant Europharm, owned by GlaxoSmithKline (GSK) which plans to close it by the end of next year, generated overall revenue worth EUR576 million and net profit of EUR28 mill...